Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Arsanilic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.36 |
| ▸ | CA4 known ✓ | P22748 | 2/20 | 0.36 |
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.36 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.36 |
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL886902 | 0.88 | CYP2C19 (0.53) | TSHRKDM4ERAB9AALDH1A1NT5E | |
| Arsanilic Acid SCHEMBL31473000 | 0.80 | CA4 (0.56) | TSHRKDM4ERAB9AALDH1A1NT5E | |
| Arsanilic Acid SCHEMBL4837583 | 0.77 | KDM4E (1.00) | TSHRKDM4ERAB9AALDH1A1NT5E | |
| Arsanilic Acid SCHEMBL160507 | 0.77 | KDM4E (1.00) | TSHRKDM4ERAB9AALDH1A1NT5E | |
| SCHEMBL28056036 | 0.76 | TSHR (0.68) | TSHRKDM4ERAB9AALDH1A1NT5E | |
| Arsanilic Acid SCHEMBL5051668 | 0.75 | KDM4E (0.95) | TSHRKDM4ERAB9AALDH1A1NT5E | |
| Arsanilic Acid SCHEMBL31473003 | 0.75 | TSHR (0.95) | TSHRKDM4ERAB9AALDH1A1NT5E | |
| SCHEMBL4407102 | 0.71 | TSHR (0.45) | TSHRKDM4ERAB9AALDH1A1NT5E | |
| Difetarsone SCHEMBL5058528 | 0.70 | ALDH1A1 (0.43) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| Difetarsone SCHEMBL160476 | 0.70 | ALDH1A1 (0.43) | ALDH1A1MAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2744790-B1 | FUNGICIDAL SUBSTITUTED 1-{2-[2-HALO-4-(4-HALOGEN-PHENOXY)-PHENYL]-2-ALKOXY-2-ALKYNYL/ALKENYL-ETHYL}-1H-[1,2,4]TRIAZOLE COMPOUNDS | BASF SE (DE) | 2016-04-27 | — | — | EP | claimed |
| CN-101214397-A | Medicament elution bracket for promoting esoderma repair and preventing vascular restenosis | WEI YANG (CN) | 2008-07-09 | — | — | CN | claimed |
| EP-1757607-A1 | N5-substituted benzo¬2,3|azepino¬4,5-b|indol-6-ones for treating tropical diseases | Molisa GmbH (DE) | 2007-02-28 | — | — | EP | claimed |
| US-20250387364-A1 | ARSINOTHRICIN AND METHODS OF TREATING INFECTIONS USING ARSINOTHRICIN | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4664445-A1 | PHYSICAL COMPRESSION DEVICE WITH ARTIFICIAL INTELLIGENCE ASSISTANCE, ON A SYMBOL STAGE, EQUIVALENT PROJECTION OF SEVERAL LEVELS OF ARRANGEMENT BY VIRTUAL PIANO | Valéry-Daulon, Marc (FR) | 2025-12-17 | — | — | EP | disclosed |
| US-12414932-B2 | Arsinothricin and methods of treating infections using arsinothricin | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250241885-A1 | ARSINOTHRICIN AND METHODS OF TREATING INFECTIONS USING ARSINOTHRICIN | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2025-07-31 | — | — | US | disclosed |
| US-12303485-B2 | Arsinothricin and methods of treating infections using arsinothricin | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2025-05-20 | — | — | US | disclosed |
| CN-119776293-A | ArsL mutant and application thereof in synthesis of Arsinothricin | 上海交通大学 | 2025-04-08 | — | — | CN | disclosed |
| WO-2024232889-A1 | ENHANCING BOREHOLE RESONANCE SIGNAL FOR THROUGH TUBING CEMENT EVALUATION | HALLIBURTON ENERGY SERVICES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-12134695-B2 | Aqueous binder formulation based on functionalized polyurethanes | BASF SE (DE) | 2024-11-05 | — | — | US | disclosed |
| EP-0185393-A1 | Process for decontaminating the surface of an object | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1986-06-25 | — | — | EP | disclosed |
| US-4569836-A | Cancer treatment by intracellular hyperthermia | GORDON, DAVID, SKOKIE, ILLINOIS | 1986-02-11 | — | — | US | disclosed |
| US-4554959-A | Surface treatment of sheet material | RY AB, FACK (SE) | 1985-11-26 | — | — | US | disclosed |
| EP-0002596-B1 | METHOD FOR REDUCING THE AMOUNT OF FREE FORMALDEHYDE IN AN AMINO FORMALDEHYDE RESIN | BEROL KEMI AB (SE) | 1983-07-27 | — | — | EP | disclosed |
| US-4359453-A | Atherosclerosis treatment method | GORDON, DAVID, SKOKIE, ILLINOIS | 1982-11-16 | — | — | US | disclosed |
| US-4303636-A | Cancer treatment | GORDON, DAVID, SKOKIE, ILLINOIS | 1981-12-01 | — | — | US | disclosed |
| EP-0002596-A1 | Method for reducing the amount of free formaldehyde in an amino formaldehyde resin | BEROL KEMI AB (SE) | 1979-06-27 | — | — | EP | disclosed |
| EP-0001485-A2 | Herbicidal sulphonamides, their preparation, compositions containing them and use thereof | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-04-18 | — | — | EP | disclosed |
| US-4106488-A | Cancer treatment method | GORDON, DAVID, SKOKIE, ILLINOIS | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387364-A1 | ARSINOTHRICIN AND METHODS OF TREATING INFECTIONS USING ARSINOTHRICIN | ARSA, NAT1, NAA15 | THRB 343/4885CA4 3529/4885CA1 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.